AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31623498 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (20 mg/d) and (15 mg/d)
Number of subjects: 3162
Study 31623498 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3162
Study 29132740 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotics (12 g/day of Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides)
Number of subjects: 60
Study 29132740 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotics
Number of subjects: 60
Study 29132740 — intervention group
Group type: COMPARATOR
Intervention: Medium absorption complex carbohydrate
Number of subjects: 60
Study 26426092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 30
Study 26426092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26426092 — intervention group
Group type: COMPARATOR
Intervention: Overall SELECT population
Number of subjects: 30
Study 23328338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (0.1 g tid) for 3 days followed by oral tramadol (0.1 g tid) for 4 days
Number of subjects: 112
Study 23328338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib (40 mg bid) for 3 days followed by oral celecoxib (0.2 mg bid) for 4 days
Number of subjects: 112
Study 23328338 — intervention group
Group type: COMPARATOR
Intervention: Intravenous parecoxib (40 mg bid) for 3 days
Number of subjects: 112
Study 23328338 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol (0.1 g tid) for 3 days
Number of subjects: 112
Study 21209300 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSS-supported planning group
Number of subjects: 80
Study 21209300 — intervention group
Group type: COMPARATOR
Intervention: Usual care planning group
Number of subjects: 80
Study 19144094 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 71
Study 19144094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 71
Study 19144094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study 17702193 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of nifuratel
Number of subjects: 24
Study 17702193 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of nifuratel
Number of subjects: 24
Study 15025738 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan at 0.05 micro g kg(‐1) min(‐1)
Number of subjects: 24
Study 15025738 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan at 0.1 micro g kg(‐1) min(‐1)
Number of subjects: 24
Study 15025738 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (both doses)
Number of subjects: 24
Study 11490051 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop and feedback reports only
Number of subjects: 113
Study 11490051 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop and feedback reports with clinical consultation
Number of subjects: 113
Study 11490051 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 113
Study 9734737 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids, glucose, and lipid infusion for 3 hours
Number of subjects: 14
Study 8291598 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops, six times, one drop every three hours until 90 minutes preoperatively
Number of subjects: 51
Study 8291598 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% eyedrops, two additional instillations, one drop every 30 minutes until 30 minutes before aspiration
Number of subjects: 51
Study 8291598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin, single 200‐mg dose
Number of subjects: 51
Study 8291598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin, 200 mg infusion
Number of subjects: 51
Study 31008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal thickness measurement
Number of subjects: 37
Study 31008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal thickness < 11.4 mm
Number of subjects: 37
Study 31008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric measurements
Number of subjects: 37
Study 31008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected volume comparison
Number of subjects: 37
Study 31008690 — intervention group
Group type: COMPARATOR
Intervention: Postoperative MTG comparison
Number of subjects: 37
Study 30783328 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin topical solution (1000 IU/ml)
Number of subjects: 84
Study 30783328 — intervention group
Group type: COMPARATOR
Intervention: Heparin topical gel (200 IU/g)
Number of subjects: 84
Study 26632520 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg/wk)
Number of subjects: 111
Study 26632520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 24910102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg/kg
Number of subjects: 4
Study 24910102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 4
Study 24910102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 4
Study 24910102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 4
Study 24910102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 24910102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (all doses)
Number of subjects: 4
Study 23076752 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA patients
Number of subjects: 3
Study 23076752 — intervention group
Group type: EXPERIMENTAL
Intervention: THA patients
Number of subjects: 3
Study 23076752 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA and THA patients combined
Number of subjects: 3
Study 20459399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (24 weeks)
Number of subjects: 77
Study 20459399 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate (24 weeks)
Number of subjects: 77
Study 18096843 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 793
Study 18096843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 16636154 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition formation and implementation stages
Number of subjects: 16
Study 16636154 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition maintenance stage
Number of subjects: 16
Study 16636154 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition institutionalization stage
Number of subjects: 16
Study 16636154 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization
Number of subjects: 16
Study 16636154 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsiveness to community needs and comprehensive strategies
Number of subjects: 16
Study 16636154 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative and achievable goals
Number of subjects: 16
Study 14661491 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection rate of 5 mL/sec
Number of subjects: 100
Study 14661491 — intervention group
Group type: EXPERIMENTAL
Intervention: All study groups with injection rates of 3 ml/sec and 5 mL/sec
Number of subjects: 100
Study 14661491 — intervention group
Group type: EXPERIMENTAL
Intervention: Preselected threshold of 50 HU
Number of subjects: 100
Study 14661491 — intervention group
Group type: COMPARATOR
Intervention: Control group with injection rate of 3 ml/sec and 60 sec delay time
Number of subjects: 100
Study 10720274 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided pallidotomy
Number of subjects: 35
Study 10720274 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided pallidotomy
Number of subjects: 35
Study 10720274 — intervention group
Group type: COMPARATOR
Intervention: Control group (pallidotomy after 6 months)
Number of subjects: 35
Study 8857868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 276
Study 8857868 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 276
Study 8857868 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study 1516676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (methylcobalamin) 3 mg/day for 4 weeks
Number of subjects: 9
Study 1516676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: DIANE combined low dose treatment (2 mgr Androcur and .05 mgr of EE in 21‐day cycles)
Number of subjects: 54
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose combination (50 mgr Androcur and .05 mgr of EE in 21 day cycles)
Number of subjects: 54
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of Androcur (25‐150 mgr)
Number of subjects: 54
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose combination
Number of subjects: 54
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: DIANE
Number of subjects: 54
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose continuous method
Number of subjects: 54
Study 12266391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose combined method
Number of subjects: 54
Study 31884313 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-DBS
Number of subjects: 13
Study 31884313 — intervention group
Group type: EXPERIMENTAL
Intervention: VIM-DBS
Number of subjects: 13
Study 31884313 — intervention group
Group type: COMPARATOR
Intervention: Preoperative speech without DBS
Number of subjects: 13
Study 27734128 — intervention group
Group type: EXPERIMENTAL
Intervention: P 3‐DXAs drink
Number of subjects: 10
Study 27734128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐DXAs drink
Number of subjects: 10
Study 27734128 — intervention group
Group type: COMPARATOR
Intervention: Control drink (low in 3‐DXAs and without proanthocyanidins)
Number of subjects: 10
Study 27734128 — intervention group
Group type: COMPARATOR
Intervention: Non-sorghum drink
Number of subjects: 10
Study 26985629 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO‐201 (single‐dose intratympanic, intraoperative, thermosensitive, otic suspension of ciprofloxacin)
Number of subjects: 532
Study 26985629 — intervention group
Group type: COMPARATOR
Intervention: TTP only (control group)
Number of subjects: 532
Study 26985629 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO‐201
Number of subjects: 532
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized high-dose imatinib
Number of subjects: 1524
Study 24297946 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/day
Number of subjects: 1524
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed MR(4.5)
Number of subjects: 1524
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib
Number of subjects: 1524
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Early major molecular remission
Number of subjects: 1524
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 1524
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 1524
Study 24297946 — intervention group
Group type: EXPERIMENTAL
Intervention: No patient with confirmed MR(4.5)
Number of subjects: 1524
Study 21484793 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brush device for hrHPV testing (self-sampling group, n = 26,145)
Number of subjects: 26409
Study 21484793 — intervention group
Group type: COMPARATOR
Intervention: Recall for regular cytology-based screening (recall control group, n = 264)
Number of subjects: 26409
Study 19401825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 1257
Study 19401825 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 1257
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen: pantoprazole 40 mg and amoxicillin 1 g for 7 days, followed by pantoprazole 40 mg, tetracycline 500 mg, and metronidazole 500 mg for the next 7 days.
Number of subjects: 300
Study 18405790 — intervention group
Group type: COMPARATOR
Intervention: PAC group: pantoprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg for 14 days.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking patients in sequential group.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking patients in sequential group.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking patients in PAC group.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking patients in PAC group.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events reported.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential group adverse events.
Number of subjects: 300
Study 18405790 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC group adverse events.
Number of subjects: 300
Study 15986288 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dilatation of dominant stenoses in PSC patients
Number of subjects: 106
Study 15986288 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CA19-9 levels in PSC patients
Number of subjects: 106
Study 15986288 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of dominant stenoses
Number of subjects: 106
Study 12566675 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 60
Study 12566675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10233049 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol.kg-1.min-1)
Number of subjects: 12
Study 10233049 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 7815178 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (800 micrograms/d)
Number of subjects: 12
Study 7815178 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc intake (3.5 mg/d or 14.5 mg/d)
Number of subjects: 12
Study 7815178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2016011 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed to patients with clinical signs and symptoms of pharyngitis.
Number of subjects: 358
Study 2016011 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics effective against Mycoplasma and Chlamydia.
Number of subjects: 358
Study 2016011 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected costs of drug treatment for patients with NSP.
Number of subjects: 358
Study 7073802 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat high polyunsaturated fat diet (MOD)
Number of subjects: 35
Study 7073802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LO)
Number of subjects: 35
Study 30325775 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected Arab MSM (AMSM)
Number of subjects: 1143
Study 30325775 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 infected Jewish MSM (JMSM)
Number of subjects: 1143
Study 30325775 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of MSM
Number of subjects: 1143
Study 29888971 — intervention group
Group type: EXPERIMENTAL
Intervention: BladderScan® BVI 6100 ultrasound device
Number of subjects: 190
Study 27250828 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy
Number of subjects: 29
Study 27250828 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy
Number of subjects: 29
Study 24256483 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vasopressor system (phenylephrine 50 μg or ephedrine 4 mg)
Number of subjects: 213
Study 24256483 — intervention group
Group type: COMPARATOR
Intervention: Manual boluses (phenylephrine 100 μg or ephedrine 8 mg)
Number of subjects: 213
Study 24256483 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vasopressor system
Number of subjects: 213
Study 24256483 — intervention group
Group type: COMPARATOR
Intervention: Manual boluses
Number of subjects: 213
Study 22784862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BIS anesthesia
Number of subjects: 40
Study 20035337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MD) with high intake of virgin olive oil (VOO)
Number of subjects: 737
Study 20035337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MD) with high intake of nuts
Number of subjects: 737
Study 20035337 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 737
Study 18544145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (5 mg.kg(‐1) intramuscular)
Number of subjects: 47
Study 18544145 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (3% concentration, increased after every three breaths)
Number of subjects: 47
Study 16158372 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration training (3 times weekly for 5 weeks, 35-40 Hz, 1.7-2.5 mm, Power Plate)
Number of subjects: 20
Study 16158372 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional training only)
Number of subjects: 20
Study 16158372 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration training
Number of subjects: 20
Study 16158372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 12955684 — intervention group
Group type: EXPERIMENTAL
Intervention: SF170E; modified cellulose triacetate/midflux membrane
Number of subjects: 211
Study 12955684 — intervention group
Group type: COMPARATOR
Intervention: HF80LS; polysulfone/high‐flux membrane
Number of subjects: 211
Study 12955684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 11572225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (diode 670 nm and Helium‐Neon 632.8 nm) at frequencies of 5 Hz, 292 Hz, and 9,000 Hz
Number of subjects: 150
Study 11572225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 150
Study 11572225 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonlaser therapy)
Number of subjects: 150
Study 9197961 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing cream (test cream)
Number of subjects: 0
Study 8457531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (70 mg Zn twice weekly for 1.25 years)
Number of subjects: 110
Study 8457531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 8457531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 110
Study 3537626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stim‐O‐Stam (acute: 1.24 g one hour before exercise)
Number of subjects: 11
Study 3537626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stim‐O‐Stam (chronic: 3.73 g X d‐1 for 6 d prior to exercise)
Number of subjects: 11
Study 3537626 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 29396713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 29396713 — intervention group
Group type: COMPARATOR
Intervention: IFN
Number of subjects: 0
Study 29396713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib after crossover from IFN
Number of subjects: 0
Study 26729619 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine strength products
Number of subjects: 0
Study 26729619 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium nicotine strength products
Number of subjects: 0
Study 26729619 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero nicotine strength products
Number of subjects: 0
Study 26729619 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters (smoking cessation phenotype)
Number of subjects: 0
Study 26729619 — intervention group
Group type: COMPARATOR
Intervention: Failures and Reducers (smoking phenotypes)
Number of subjects: 0
Study 24889854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain biology education (2×1 hour sessions)
Number of subjects: 202
Study 24889854 — intervention group
Group type: COMPARATOR
Intervention: Sham education (2×1 hour sessions)
Number of subjects: 202
Study 24889854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain biology education
Number of subjects: 202
Study 24889854 — intervention group
Group type: COMPARATOR
Intervention: Sham education
Number of subjects: 202
Study 21627741 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux symptoms (never, monthly or less often, weekly or more often)
Number of subjects: 2700
Study 21627741 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of OSA (23% of participants)
Number of subjects: 2700
Study 21627741 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > 25 (63% of participants, 22% > 30)
Number of subjects: 2700
Study 20088941 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose up to 100 mg three times a day
Number of subjects: 48
Study 20088941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17438254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular exercises (8 patients)
Number of subjects: 13
Study 17438254 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercises (5 patients)
Number of subjects: 13
Study 16259869 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 (144 Gy, TG-43)
Number of subjects: 352
Study 16259869 — intervention group
Group type: COMPARATOR
Intervention: Pd-103 (125 Gy, NIST-99)
Number of subjects: 352
Study 16259869 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125
Number of subjects: 352
Study 16259869 — intervention group
Group type: COMPARATOR
Intervention: Pd-103
Number of subjects: 352
Study 12451343 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5mg/day)
Number of subjects: 29
Study 12451343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10403264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg/day
Number of subjects: 236
Study 10403264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236